Adamas Pharmaceuticals Shares Outstanding 2013-2018 | ADMS

Current and historical number of shares outstanding for Adamas Pharmaceuticals (ADMS) from 2013 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Adamas Pharmaceuticals Annual Shares Outstanding
(Millions of US $)
2017 $23
2016 $22
2015 $18
2014 $17
2013 $12
2012 $10
Adamas Pharmaceuticals Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $27
Q1 2018 $26
Q4 2017 $23
Q3 2017 $23
Q2 2017 $22
Q1 2017 $22
Q4 2016 $22
Q3 2016 $22
Q2 2016 $22
Q1 2016 $21
Q4 2015 $18
Q3 2015 $18
Q2 2015 $18
Q1 2015 $18
Q4 2014 $17
Q3 2014 $17
Q2 2014 $19
Q1 2014 $10
Q4 2013 $12
Q3 2013 $10
Q2 2013 $10
Q1 2013 $11
Q4 2012 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.637B $0.001B
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.549B 10.73
Teva Pharmaceutical Industries (TEVA) Israel $22.320B 6.24
Mylan (MYL) United Kingdom $19.354B 8.23
Bausch Health Cos (BHC) Canada $7.455B 5.57
Dr Reddy's Laboratories (RDY) India $5.335B 23.83
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.637B 4.48
Akorn (AKRX) United States $2.348B 11.63
Supernus Pharmaceuticals (SUPN) United States $2.271B 24.30
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.816B 117.53
CymaBay Therapeutics (CBAY) United States $0.718B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Homology Medicines (FIXX) United States $0.587B 0.00
Voyager Therapeutics (VYGR) United States $0.574B 0.00
Corium (CORI) United States $0.336B 0.00
Teligent (TLGT) United States $0.223B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.116B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.077B 0.00
Versartis (VSAR) United States $0.060B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.040B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.022B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00